Date post: | 20-Jan-2016 |
Category: |
Documents |
Upload: | homer-hensley |
View: | 224 times |
Download: | 0 times |
1
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
New Drug Application NDA 21-572/S-008 New Drug Application NDA 21-572/S-008 CubicinCubicin® (daptomycin for injection)® (daptomycin for injection)New Drug Application NDA 21-572/S-008 New Drug Application NDA 21-572/S-008 CubicinCubicin® (daptomycin for injection)® (daptomycin for injection)
Microbiology: Increased Daptomycin MICs Microbiology: Increased Daptomycin MICs During TherapyDuring Therapy
Peter Coderre, PhD, MBAPeter Coderre, PhD, MBACDER, DAIOPCDER, DAIOPAnti-Infective Drugs Advisory Committee MeetingAnti-Infective Drugs Advisory Committee MeetingRockville, MarylandRockville, MarylandMarch 6, 2006March 6, 2006
Microbiology: Increased Daptomycin MICs Microbiology: Increased Daptomycin MICs During TherapyDuring Therapy
Peter Coderre, PhD, MBAPeter Coderre, PhD, MBACDER, DAIOPCDER, DAIOPAnti-Infective Drugs Advisory Committee MeetingAnti-Infective Drugs Advisory Committee MeetingRockville, MarylandRockville, MarylandMarch 6, 2006March 6, 2006
2
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
Increased Daptomycin MICsIncreased Daptomycin MICsIncreased Daptomycin MICsIncreased Daptomycin MICs
• Increasing daptomycin MICs documented in vitro, in vivo, in the literature and during this clinical trial
• Currently: S. aureus isolates with a MIC ≤ 1 g/ml are considered susceptible to daptomycin
• Breakpoints for intermediate and resistant isolates have yet to be established
• Increasing daptomycin MICs documented in vitro, in vivo, in the literature and during this clinical trial
• Currently: S. aureus isolates with a MIC ≤ 1 g/ml are considered susceptible to daptomycin
• Breakpoints for intermediate and resistant isolates have yet to be established
3
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
Increased Daptomycin MICsIncreased Daptomycin MICsIncreased Daptomycin MICsIncreased Daptomycin MICs
What are the implications of increasing daptomycin MICs during treatment with daptomycin for infective endocarditis and bacteremia?
In patients with persistent or relapsing bacteremia, S. aureus demonstrated increasing daptomycin MICs (≥ 1 g/ml) during or after therapy with the drug.
What are the implications of increasing daptomycin MICs during treatment with daptomycin for infective endocarditis and bacteremia?
In patients with persistent or relapsing bacteremia, S. aureus demonstrated increasing daptomycin MICs (≥ 1 g/ml) during or after therapy with the drug.
4
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
Changes in MICs for Relapsing or Persistent Bacteremia Patients#
Changes in MICs for Relapsing or Persistent Bacteremia Patients#
MIC >1> 2
steps MRSA MSSA
daptomycin arm (N=20)
9/20 (45.0%)
9/20 (45.0%)
12/20 (60.0%)*
11/20 (55.0%)*
comparator arm (N=10)
1/10 (10.0%)
0/10 (0%)
8/10 (80.0%)
2/10 (20.0%)
3 patients had both MSSA and MRSA # FDA Analysis
5
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
Distribution of Terminal MICs for Daptomycin Treated Patients (ITT) by
Clinical Outcome
Distribution of Terminal MICs for Daptomycin Treated Patients (ITT) by
Clinical Outcome
MIC (g/ml)
0.12 0.25 0.5 1 2 4
clinical success (N=53)
1 (1.9%)
36 (67.9%)
14 (26.4%)
2 (3.8%)
0 (0%)
0 (0%)
clinical failure (N=59)
1 (1.7%)
34 (57.6%)
15 (25.4%)
3 (5.1%)
5 (8.5%)
1 (1.7%)
total (N=112)2
(1.8%)70
(62.5%)29
(25.9%)5
(4.4%)5
(4.5%)1
(0.9%)
6
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
Clinical Failures in Daptomycin Arm with Increased Daptomycin MICs
Clinical Failures in Daptomycin Arm with Increased Daptomycin MICs
Case # Final Diagnosis Organism Baseline High MIC Step
MIC MIC Increase
009-212complicated bacteremia MRSA 0.25 2 3
010-152 complicated RIE MSSA 0.25 4 4
015-105complicated bacteremia Both 0.25 2 -
017-037 left IE Both 0.25 2 -
027-183 left IE MRSA 0.5 2 2
324-136complicated bacteremia MRSA 0.5 2 2
300-111 left IE MRSA 0.25 1 2
300-246 left IE MRSA 0.25 1 2
7
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
Frequency of Increased MICs and Non-Susceptibility/Resistance to Daptomycin or
Vancomycin in Patients during Therapy^
Frequency of Increased MICs and Non-Susceptibility/Resistance to Daptomycin or
Vancomycin in Patients during Therapy^
N, % ↑ N, % ↑ N, %
developed N, %
developed
Dapto MIC Vanco MIC DaptoNS VancoR
IEAC successes
daptomycin (N=53) 17 (32.1%)* 12 (22.6%)* 0 (0%)* 0 (0%)*
comparator (N=48) 11 (22.9%) 13 (27.1%) 1 (2.1%) 0 (0%)
IEAC failures
daptomycin (N=67) 23 (34.3%) 16 (24.2%)* 6 (9.0%) 0 (0.0%)*
comparator (N=65) 12 (18.5%)* 17 (26.2%)* 0 (0.0%)** 0 (0.0%)**
*determination of MICs not done for one patient; **determination of MICs not done for two patients; *** one or more dilution increase; ^ contains non-evaluable patients as failures
8
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
Overview of Isolates with Treatment Associated Decreases in Daptomycin Susceptibility Following
Commercial Availability
Overview of Isolates with Treatment Associated Decreases in Daptomycin Susceptibility Following
Commercial Availability
Isolate/N Source Daptomycin MIC (g/ml)
S.aureus blood 0.25 1
S.aureus * 0.25 4
S.aureus--5 blood 0.5 4
S.aureus ** 0.5 4
S.aureus blood 1 2--4
S.aureus 0.5 8
MRSA 0.25 1.5
E. faecium urine/blood 4 32
E. faecium blood 4 > 32
VRE*** blood 4
VRE*** 8
9
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
Recent Literature Reporting Clinical Failures with Daptomycin TreatmentRecent Literature Reporting Clinical Failures with Daptomycin Treatment
Organism Condition Source Dose Highest Reference
(mg/kg) MIC (g/ml)
MRSA bacteremia blood 4 2 Mangili et al., 2005
MRSA osteomyelitis blood 6 4 Hayden et al., 2005
MRSA bacteremia blood 8 4 Skiest, 2006
MRSA bacteremia blood 6 4 Marty et al., 2006
E. faecium bacteremia blood 6 >32 Sabol et al., 2005
E. faecium fever blood none 4 Lesho et al., 2006
E. faecalis (VRE) bacteremia blood * 16 Munoz-Price, et al., 2005
E. faecalis (VRE) febrile neutropenia blood ?? ?? Long et al., 2005
*400 mg q48h
10
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
Surveillance DataSurveillance Data
Species Study/Year
N Daptomycin MIC Distribution n (%) MIC (g/ml)
≤ 0.12 0.25 0.5 1 2
MSSA 2000-1 1601 304 (18.9%) 1165 (72.7%) 131 (8.2%) 1 (0.1%) 0 (0%)
2002 1547 83 (5.4%) 1140 (73.7%) 319 (20.6%) 3 (0.2%) 2 (0.1%)
2003 2894 229 (7.9%) 2371 (81.9%) 285 (9.9%) 8 (0.3%) 1 (<0.1%)
2003-4 3284 70 (2.1%) 1891 (57.6%) 1297 (39.5%) 25 (0.8%) 1 (<0.1%)
MRSA 2000-1 639 51 (7.9%) 396 (61.9%) 187 (29.3%) 5 (0.8%) 0 (0%)
2002 1076 20 (1.9%) 655 (60.9%) 388 (36.1%) 13 (1.2%) 0 (0%)
2003 1468 40 (2.7%) 963 (65.6%) 452 (30.8%) 13 (0.9%) 0 (0%)
2003-4 1976 10 (0.5%) 878 (44.4%) 1047 (52.9%) 40 (2.0%) 1 (<0.1%)
Source: Table 2.7.2-24, NDA 21-572 SN008
11
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
S. aureus S. aureus MIC Distributions: 2004-2005 MIC Distributions: 2004-2005 (2004: n = 317; 2005: n = 359)(2004: n = 317; 2005: n = 359)
S. aureus S. aureus MIC Distributions: 2004-2005 MIC Distributions: 2004-2005 (2004: n = 317; 2005: n = 359)(2004: n = 317; 2005: n = 359)
0.9% 3.3%
0102030405060708090
100
< 1 (g/ml) > 1 (g/ml)MIC Group
% o
f T
ota
l
99.1% 96.7%
Source: Focus Technologies
2004 2005 2004 2005
12
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
In VivoIn Vivo Evidence EvidenceIn VivoIn Vivo Evidence Evidence
• Sponsor data from rabbits, mice, rats for bacteremia, endocarditis, fibrin clot, etc.
• In rabbit model, daptomycin more efficacious than vancomycin, however, diminished susceptibility developed during therapy —due to selection by sub-inhibitory concentrations of daptomycin in vegetations
• Silverman et al. (2001): extensive clinical use required to establish if resistance will be a major clinical problem
• Sponsor data from rabbits, mice, rats for bacteremia, endocarditis, fibrin clot, etc.
• In rabbit model, daptomycin more efficacious than vancomycin, however, diminished susceptibility developed during therapy —due to selection by sub-inhibitory concentrations of daptomycin in vegetations
• Silverman et al. (2001): extensive clinical use required to establish if resistance will be a major clinical problem
13
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
In VitroIn Vitro Evidence EvidenceIn VitroIn Vitro Evidence Evidence
• Spontaneous mutations rare; no known transferable elements
• Liebowitz et al. (1988): stable resistant organisms after multiple passages in increasing [daptomycin] and after chemical mutagenesis— isolates 16X higher than parental isolates
• Kaatz et al. (1990): DaptoR mutants were VanS, AmpS but cross-resistance to Nisin
• Spontaneous mutations rare; no known transferable elements
• Liebowitz et al. (1988): stable resistant organisms after multiple passages in increasing [daptomycin] and after chemical mutagenesis— isolates 16X higher than parental isolates
• Kaatz et al. (1990): DaptoR mutants were VanS, AmpS but cross-resistance to Nisin
14
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
In VivoIn Vivo Evidence--Biofilms Evidence--BiofilmsIn VivoIn Vivo Evidence--Biofilms Evidence--Biofilms
• Evidence for pathogenesis of biofilms in IE is strong
• 60% of daptomycin penetrates vegetation but 90% is protein bound; therefore, expect < 60% penetration
• Vegetations manifest biofilm-like antibiotic resistance that cannot be completely explained by poor penetration of antimicrobials
• Composition of the valve biofilm has direct bearing on clinical outcomes
• Results demonstrate association between biofilm composition and clinical manifestations—IE can be manipulated by targeting biofilm development
• Evidence for pathogenesis of biofilms in IE is strong
• 60% of daptomycin penetrates vegetation but 90% is protein bound; therefore, expect < 60% penetration
• Vegetations manifest biofilm-like antibiotic resistance that cannot be completely explained by poor penetration of antimicrobials
• Composition of the valve biofilm has direct bearing on clinical outcomes
• Results demonstrate association between biofilm composition and clinical manifestations—IE can be manipulated by targeting biofilm development
15
Center for Drug Evaluation and ResearchCenter for Drug Evaluation and ResearchAnti-Infective Drug Advisory Committee Anti-Infective Drug Advisory Committee March 6, 2006March 6, 2006
SummarySummarySummarySummary
• On therapy (endocarditis): increasing daptomycin MICs particularly among persisting or relapsing bacteremia
• On therapy (all-comers): increasing daptomycin MICs among clinical failures
• Surveillance data: increasing daptomycin MICs over time; more reports in literature (2005-6) showing daptomycin resistance
• In vivo: rabbit model, daptomycin more efficacious than vancomycin but diminished daptomycin susceptibility during therapy
• In vitro: bacteria develop resistance at sub-inhibitory concentrations; cross-resistance to nisin, but not vancomycin or ampicillin; biofilms—subinhibitory concentrations?
• On therapy (endocarditis): increasing daptomycin MICs particularly among persisting or relapsing bacteremia
• On therapy (all-comers): increasing daptomycin MICs among clinical failures
• Surveillance data: increasing daptomycin MICs over time; more reports in literature (2005-6) showing daptomycin resistance
• In vivo: rabbit model, daptomycin more efficacious than vancomycin but diminished daptomycin susceptibility during therapy
• In vitro: bacteria develop resistance at sub-inhibitory concentrations; cross-resistance to nisin, but not vancomycin or ampicillin; biofilms—subinhibitory concentrations?